In conclusion, we demonstrated that overexpression of MOS and TPL2 is associated with BCR::ABL1‐independent dasatinib resistance in CML cells and that inhibition of MOS and TPL2 or ERK1/2 activation by MEK1/2 inhibitor overcomes dasatinib resistance (Figure 5). Here, MAPK3 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.